Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Faron Pharmaceuticals
Faron Pharmaceuticals
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
New patent protects the intravenous use of interferon-beta in a novel formulation
Faron has developed the first intravenous formulation of IFN-beta to enable the treatment of vascular leakage in lungs and other central organs
Manufacturing
Abzena to manufacture therapeutic antibody for Faron
Clevegen is a novel therapeutic antibody being developed by Faron to reduce immune suppression in cancer
Research & Development
Faron strengthens executive team by appointing new Medical Director
He will play a central role in expanding the Finnish firm's clinical programmes of drug candidates
Research & Development
Faron links up with Selexis to progress development of cancer antibody
Under the agreement, Faron will have access to the Selexis SUREtechnology platform and SURE CHO-M cell line
Ingredients
Rentschler to manufacture Traumakine for Faron
German contract manufacturer first produced product in 1980s
Subscribe now